摘要
目的:分析原发生肝癌患者是否存在胰岛素抵抗及胰岛素抵抗与肝癌临床疗效的关系。方法:选择2005年1月～2008年12月在我院住院治疗的原发性肝癌患者71例作为观察组,另选择75例正常人作为对照组,分别测定肝癌患者治疗前、治疗后1月及对照组空腹和餐后2小时的血糖及胰岛素,计算胰岛素抵抗指数(IRI),并比较肝癌患者治疗前后的IRI。结果:肝癌组胰岛素抵抗指数IRI为3.11±0.42,高于对照组1.98±0.70(P<0.05);经过治疗后,肝癌组胰岛素抵抗指数IRI下降;且肝癌切除组IRI下降最多,达1.16;结论:原发性肝癌患者中,存在胰岛素抵抗,胰岛素抵抗与患者的临床疗效有一定关系。
Objective： To explore the insulin resistance in Primary hepatocellular carcinoma and the relationship between insulin resistance and clinical efficacy in primary hepatocellular carcinoma. Methods： From Jan. 2005 to Dec. 2008, 71 cases of primary hepatocellular carcinoma were enrolled in the study, and 75 normal cases were selected as controls. Blood glucose and insulin at fasting and two-hour postprandial time points of normal people and pre-treatment and one month after treatment of patients were measured. The insulin resistance index （IRI） were calculated, and the IRI of primary hepatoeellular carcinoma beA＇ore and after the treatment were compared. Results： IRI of primary hepatocelhilar carcinoma group was 3. 11 ±0. 42, which was higher than that of control group： 1.98 ±0. 70（ P 〈0. 05 ）. After treatment, the IRI of primary hepatocellular carcinoma dropped. Conclusion： The insulin resistance exists in primary hepatoeellular carcinoma. There is relationship between insulin resistance and the clinical effecacy of primary hepatocellular carcinoma patients.
出处
《肿瘤预防与治疗》
2010年第5期405-406,409,共3页
Journal of Cancer Control And Treatment
关键词
肝癌/原发性
胰岛素抵抗
血糖
Primary Hepatocellular Carcinoma
Insulin Resistance
Glucose
